Cambrex To Expand Chemical and Analytical CapabilitiesBy
Cambrex, an East Rutherford, New Jersey-based contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), has announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant. The project forms part of the company’s strategic plan to increase its development capacity and resources in North America.
The expansion will see the construction of an additional 2,000 square feet of laboratory space for development projects and is expected to support the hiring of an additional 14 chemists. The building, installation, and validation of equipment is expected to be completed by the first quarter of 2018.
The expansion at the Charles City plant occurs alongside investments announced in 2017 at Cambrex’s facility in High Point, North Carolina, where a new 11,000-square-foot analytical laboratory and 400-square-foot pilot plant with a total reactor capacity of 4,000 liters are currently being completed. These expansions at High Point will create up to 18 new jobs.
Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The High Point site, formerly PharmaCore, was acquired by Cambrex in October 2016, and produces APIs and intermediates in batch sizes from milligrams to 100 kg to support clinical trials from Phase I to Phase III.